Pityriasis alba: toward an effective treatment

Area of Science:

• Dermatology
• Clinical Research
• Pharmacology

Background:

• Pityriasis alba (PA) is a common skin condition.
• Hypopigmentation in PA is a significant cosmetic concern, particularly in darker skin types.
• Effective and cost-effective treatments for PA are needed.

Purpose of the Study:

• To evaluate the efficacy of three cost-effective topical treatments for pityriasis alba (PA).
• To compare the effectiveness of Calcipotriol 0.005% cream, Tacrolimus 0.03% ointment, and Clobetasone butyrate 0.05% cream against a placebo.

Main Methods:

• A prospective study involving 80 patients with PA.
• Patients were divided into four groups receiving topical treatments or placebo twice daily for 8 weeks.
• Evaluations included clinical assessment, Physician Global Assessment, patient satisfaction, and planimetry.

Main Results:

• All three active treatments showed superiority over placebo in improving scaling, erythema, and hypopigmentation.
• Tacrolimus 0.03% ointment demonstrated superior repigmentation compared to Calcipotriol and Clobetasone butyrate.
• Clobetasone butyrate 0.05% cream achieved the highest patient satisfaction levels.

Conclusions:

• Topical Calcipotriol, Tacrolimus, and Clobetasone butyrate are effective treatments for pityriasis alba.
• Tacrolimus 0.03% ointment offers a favorable option due to its efficacy and limited side effects.
• Further research may explore optimal treatment durations and combinations for PA management.